Balchem (BCPC) 10-Q 3 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	Apr. 25, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	BALCHEM CORP
Entity Central Index Key	0000009326
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		32,333,546
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 39,004	$ 54,268
Accounts receivable, net of allowance for doubtful accounts of $583 and $610 at March 31, 2019 and December 31, 2018 respectively	99,834	99,545
Inventories	66,764	67,187
Prepaid expenses	3,510	3,830
Assets held for sale	11,748	0
Other current assets	806	1,484
Total current assets	221,666	226,314
Property, plant and equipment, net	188,036	194,339
Goodwill	446,453	447,995
Intangible assets with finite lives, net	100,088	105,985
Right of use assets	8,036	0
Other assets	7,609	6,722
Total assets	971,888	981,355
Current liabilities:
Trade accounts payable	26,342	33,345
Accrued expenses	20,922	22,025
Accrued compensation and other benefits	6,255	11,022
Dividends payable	78	15,220
Income tax payable	6,989	444
Lease liabilities - current	2,467	0
Liabilities held for sale	757	0
Total current liabilities	63,810	82,056
Revolving loan	140,000	156,000
Deferred income taxes	44,311	44,309
Lease liabilities - non-current	5,559	0
Other long-term obligations	7,699	7,372
Total liabilities	261,379	289,737
Commitments and contingencies (note 16)
Stockholders' equity:
Preferred stock, $25 par value. Authorized 2,000,000 shares; none issued and outstanding	0	0
Common stock, $.0667 par value. Authorized 120,000,000 shares; 32,336,228 shares issued and 32,330,032 outstanding at March 31, 2019 and 32,256,915 shares issued and 32,256,209 outstanding at December 31, 2018, respectively	2,156	2,151
Additional paid-in capital	166,762	165,098
Retained earnings	546,810	528,027
Accumulated other comprehensive loss	(4,686)	(3,602)
Treasury stock, at cost: 6,196 and 706 shares at March 31, 2019 and December 31, 2018	(533)	(56)
Total stockholders' equity	710,509	691,618
Total liabilities and stockholders' equity	$ 971,888	$ 981,355

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Allowance for doubtful accounts	$ 583	$ 610
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 25	$ 25
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0667	$ 0.0667
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	32,336,228	32,256,915
Common stock, shares outstanding (in shares)	32,330,032	32,256,209
Treasury stock (in shares)	6,196	706

Condensed Consolidated Statemen

Condensed Consolidated Statements of Earnings - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Net sales	$ 157,029	$ 161,410
Cost of sales	107,934	109,951
Gross margin	49,095	51,459
Operating expenses:
Selling expenses	14,126	14,059
Research and development expenses	2,895	2,569
General and administrative expenses	5,594	7,591
Total operating expenses	22,615	24,219
Earnings from operations	26,480	27,240
Other expenses:
Interest expense, net	1,589	1,874
Other, net	98	189
Total other expenses (income)	1,687	2,063
Earnings before income tax expense	24,793	25,177
Income tax expense	6,010	5,831
Net earnings	$ 18,783	$ 19,346
Net earnings per common share - basic (in dollars per share)	$ 0.58	$ 0.60
Net earnings per common share - diluted (in dollars per share)	$ 0.58	$ 0.60

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Statement of Comprehensive Income [Abstract]
Net earnings	$ 18,783	$ 19,346
Other comprehensive (loss) income, net of tax:
Net foreign currency translation adjustment	(1,089)	1,363
Net change in postretirement benefit plans, net of taxes of $(2) and $(4) for the three months ended March 31, 2019 and 2018	5	13
Other comprehensive (loss) income	(1,084)	1,376
Comprehensive income	$ 17,699	$ 20,722

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Other comprehensive (loss) income, net of tax:
Net change in postretirement benefit plan, taxes	$ (2)	$ (4)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Common Stock	Treasury Stock	Additional Paid-in Capital
Beginning balance at Dec. 31, 2017	$ 616,881	$ 464,639	$ (1,642)	$ 2,135	$ 0	$ 151,749
Beginning balance (in shares) at Dec. 31, 2017				32,019,605	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	19,346	19,346
Other comprehensive (loss) income	1,376		1,376
Dividends	1	1
Treasury shares purchased	(786)				$ (786)
Treasury shares purchased (in shares)					(10,454)
Shares and options issued under stock plans	3,072			$ 5	$ 786	2,281
Shares and options issued under stock plans (in shares)				80,505	10,454
Ending balance at Mar. 31, 2018	639,890	483,986	(266)	$ 2,140	$ 0	154,030
Ending balance (in shares) at Mar. 31, 2018				32,100,110	0
Beginning balance at Dec. 31, 2018	691,618	528,027	(3,602)	$ 2,151	$ (56)	165,098
Beginning balance (in shares) at Dec. 31, 2018				32,256,209	(706)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	18,783	18,783
Other comprehensive (loss) income	(1,084)		(1,084)
Treasury shares purchased	(727)				$ (727)
Treasury shares purchased (in shares)					(8,496)
Shares and options issued under stock plans	1,919			$ 5	$ 250	1,664
Shares and options issued under stock plans (in shares)				73,823	3,006
Ending balance at Mar. 31, 2019	$ 710,509	$ 546,810	$ (4,686)	$ 2,156	$ (533)	$ 166,762
Ending balance (in shares) at Mar. 31, 2019				32,330,032	(6,196)

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net earnings	$ 18,783	$ 19,346
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	10,836	11,127
Stock compensation expense	1,631	1,793
Deferred income taxes	35	(38)
Provision for (recovery of) doubtful accounts	88	(69)
Foreign currency transaction loss	50	51
Asset impairment charge	114	71
Gain on disposal of assets	(2,719)	(1,093)
Changes in assets and liabilities
Accounts receivable	(912)	(4,340)
Inventories	(139)	(5,442)
Prepaid expenses and other current assets	972	345
Accounts payable and accrued expenses	(12,389)	(2,273)
Income taxes	6,575	5,633
Other	(442)	368
Net cash provided by operating activities	22,483	25,479
Cash flows from investing activities:
Capital expenditures	(8,488)	(3,735)
Proceeds from insurance	2,727	1,590
Intangible assets acquired	(19)	(119)
Net cash used in investing activities	(5,780)	(2,264)
Cash flows from financing activities:
Principal payments on revolving loan	(16,000)	0
Principal payments on long-term debt	0	(8,750)
Proceeds from stock options exercised	288	1,261
Dividends paid	(15,135)	(13,421)
Purchase of treasury stock	(727)	(786)
Net cash used in financing activities	(31,574)	(21,696)
Effect of exchange rate changes on cash	(393)	744
(Decrease) increase in cash and cash equivalents	(15,264)	2,263
Cash and cash equivalents beginning of period	54,268	40,416
Cash and cash equivalents end of period	$ 39,004	$ 42,679

CONDENSED CONSOLIDATED FINANCIA

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The condensed consolidated financial statements presented herein have been prepared by the Company in accordance with the accounting policies described in its December 31, 2018 consolidated financial statements, and should be read in conjunction with the consolidated financial statements and notes, which appear in the Annual Report on Form 10-K for the year ended December 31, 2018 . References in this report to the “Company” mean either Balchem Corporation or Balchem Corporation and its subsidiaries, including SensoryEffects, Inc., SensoryEffects Cereal Systems, Inc., Albion Laboratories, Inc. (formerly known as Albion International, Inc.), BCP Ingredients, Inc., Aberco, Inc., Balchem BV, Balchem Italia Srl, Bioscreen Technologies Srl, Innovative Food Processors, Inc., and Balchem LTD, on a consolidated basis, as the context requires. In the opinion of management, the unaudited condensed consolidated financial statements furnished in this Form 10-Q include all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. All such adjustments are of a normal recurring nature. The condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP” or “GAAP”) governing interim financial statements and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934 (the "Exchange Act") and therefore do not include some information and notes necessary to conform to annual reporting requirements. The results of operations for the three months ended March 31, 2019 are not necessarily indicative of the operating results expected for the full year or any interim period. Certain reclassifications have been made to prior period amounts to conform with the current period's presentation. Recent Accounting Pronouncements Recently Issued Accounting Standards In March 2019, the FASB issued ASU 2019-01, "Leases (Topic 842): Codification Improvements," which further clarifies the determination of fair value of leases and modifies transition disclosure requirements for changes in accounting principles. The effective date of the amendments is for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company is currently evaluating the impact of this pronouncement on the Company’s consolidated financial statements and disclosures. As stated below, the Company adopted Accounting Standards Codification ("ASC") 842 ("ASU 2016-02), Leases, as of January 1, 2019. In August 2018, the FASB issued ASU 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.” The guidance requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the noncancelable term of the cloud computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2) for which exercise of the renewal option is controlled by the cloud service provider. The effective date of this pronouncement is for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted and the standard may be adopted either using the prospective or retrospective transition approach. The Company is currently evaluating the impact of this pronouncement on the Company’s consolidated financial statements and disclosures. In August 2018, the FASB issued ASU 2018-14, “Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans,” which modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement benefit plans. The guidance removes disclosures that are no longer considered cost beneficial, clarifies the specific requirements of disclosures and adds disclosure requirements identified as relevant. This update should be applied on a retrospective basis to all periods presented and is effective for fiscal years ending after December 31, 2020. Early adoption is permitted. The Company expects this new guidance will have minimal impact on its financial reporting. In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment” (ASU 2017-04), which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. The guidance is effective for annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted; however, the Company has elected not to adopt early as this ASU will not have a significant impact on the Company’s consolidated financial statements. Recently Adopted Accounting Standards In February 2016, the FASB issued ASU No. 2016-02, “Leases” (“ASU 2016-02”), which was clarified by ASU 2018-11 and addresses the recognition of assets and liabilities that arise from all leases. The guidance requires lessees to recognize right-of-use assets

SIGNIFICANT ACQUISITIONS AND DI

SIGNIFICANT ACQUISITIONS AND DIVESTITURES	3 Months Ended
	Mar. 31, 2019
Business Combinations [Abstract]
SIGNIFICANT ACQUISITIONS AND DIVESTITURES	SIGNIFICANT ACQUISITIONS AND DIVESTITURES The Company did not complete any acquisitions during the three months ended March 31, 2019 or 2018 . Total transaction and integration costs related to recent acquisitions, including the subsequent event identified below, are recorded in general and administrative expenses and amounted to $485 and $689 for the three months ended March 31, 2019 and 2018, respectively. Potential Divestiture As of March 31, 2019, the Company was in negotiations for the sale of an insignificant portion of the Company's business. The transaction is estimated to be completed during 2019 and no gain or loss has been recognized in the Company's condensed consolidated statements of earnings as of March 31, 2019. The related assets and liabilities have been reclassified as current assets held for sale and current liabilities held for sale within the Company's condensed consolidated balance sheets as of March 31, 2019 and include the following: March 31, 2019 Accounts receivable $ 353 Inventory 376 Property, plant, and equipment, net 9,314 Right of use assets 317 Goodwill 1,380 Other current assets 8 Assets held for sale $ 11,748 Trade accounts payable $ 126 Accrued expenses 260 Accrued compensation and other benefits 52 Lease liabilities 319 Liabilities held for sale $ 757 Subsequent Event On May 2, 2019, the Company entered into a securities purchase agreement for the acquisition of Chemogas Holding NV and its Subsidiaries ("Chemogas"), a privately held specialty gases company headquartered in Grimbergen, Belgium, for a purchase price of €95,000 , subject to certain adjustments as provided in the definitive agreement. The transaction is subject to customary conditions to closing and will be financed through the Company's Credit Agreement (as defined below) and cash on hand. Chemogas has been a leader in the packaging and distribution of a wide variety of specialty gases, most notably ethylene oxide, primarily in the European and Asian markets, for medical device sterilization. Through its operational and logistical excellence, Chemogas supports its customers' needs across more than 70 countries. With this acquisition, Balchem significantly expands its geographic presence in the packaged ethylene oxide market, enabling the Company to offer worldwide service and support to its medical device sterilization customers within the Specialty Products segment. The Chemogas sites in Europe and Asia will form a global network of facilities when combined with Balchem's sites in the United States. In connection with this transaction, the Company incurred transaction costs of $307

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	3 Months Ended
	Mar. 31, 2019
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY STOCK-BASED COMPENSATION The Company’s results for the three months ended March 31, 2019 and 2018 reflected the following stock-based compensation cost, and such compensation cost had the following effects on net earnings: Increase/(Decrease) for the 2019 2018 Cost of sales $ 288 $ 245 Operating expenses 1,343 1,548 Net earnings (1,258 ) (1,378 ) As allowed by ASC 718, the Company has made an estimate of expected forfeitures based on its historical experience and is recognizing compensation cost only for those stock-based compensation awards expected to vest. The Company’s stock incentive plans allow for the granting of stock awards and options to purchase common stock. Both incentive stock options and nonqualified stock options can be awarded under the plans. No option will be exercisable for longer than ten years after the date of grant. The Company has approved and reserved a number of shares to be issued upon exercise of the outstanding options that is adequate to cover all exercises. As of March 31, 2019 , the plans had 1,096,274 shares available for future awards. Compensation expense for stock options and stock awards is recognized on a straight-line basis over the vesting period, generally three years for stock options, three to four years for employee restricted stock awards, three years for employee performance share awards, and three to four years for non-employee director restricted stock awards. Certain awards provide for accelerated vesting if there is a change in control (as defined in the plans) or other qualifying events. Option activity for the three months ended March 31, 2019 and 2018 is summarized below: Shares (000s) Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Term Outstanding as of December 31, 2018 887 $ 61.59 $ 16,192 Granted 185 84.19 Exercised (7 ) 40.85 Forfeited — — Canceled — — Outstanding as of March 31, 2019 1,065 $ 65.64 $ 28,924 6.7 Exercisable as of March 31, 2019 685 $ 56.91 $ 24,588 5.4 Shares (000s) Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Term Outstanding as of December 31, 2017 946 $ 55.44 $ 24,714 Granted 148 74.57 Exercised (39 ) 32.83 Forfeited (1 ) 73.49 Canceled (1 ) 25.39 Outstanding as of March 31, 2018 1,053 $ 58.98 $ 24,680 6.6 Exercisable as of March 31, 2018 637 $ 48.54 $ 21,306 5.3 ASC 718 requires companies to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model with the following weighted average assumptions: dividend yields of 0.6% and 0.6% ; expected volatilities of 24% and 27% ; risk-free interest rates of 2.5% and 2.6% ; and expected lives of 4.0 years and 4.4 years , in each case for the three months ended March 31, 2019 and 2018 , respectively. The Company used a projected expected life for each award granted based on historical experience of employees’ exercise behavior. Expected volatility is based on the Company’s historical volatility levels. Dividend yields are based on the Company’s historical dividend yields. Risk-free interest rates are based on the implied yields currently available on U.S. Treasury Zero coupon issues with a remaining term equal to the expected life. Other information pertaining to option activity during the three months ended March 31, 2019 and 2018 was as follows: Three Months Ended March 31, 2019 2018 Weighted-average fair value of options granted $ 18.26 $ 18.62 Total intrinsic value of stock options exercised ($000s) $ 302 $ 1,825 Non-vested restricted stock activity for the three months ended March 31, 2019 and 2018 is summarized below: Three months ended March 31, 2019 Shares (000s) Weighted Average Grant Date Fair Value Non-vested balance as of December 31, 2018 79 $ 72.75 Granted 66 84.27 Vested (8 ) 58.52 Forfeited — — Non-vested balance as of March 31, 2019 137 $ 79.16 Three months ended March 31, 2018 Shares (000s) Weighted Average Grant Date Fair Value Non-vested balance as of December 31, 2017 66 $ 65.66 Granted 36 74.57 Vested (6 ) 50.32 Forfeited — — Non-vested balance as of March 31, 2018 96 $ 70.10 Non-vested performance share activity for the three months ended March 31, 2019 and 2018 is summarized below: Three months ended March 31, 2019 Shares (000s) Weighted Average Grant Date Fair Value Non-vested balance as of December 31, 2018 53 $ 75.61 Granted 33 81.79 Vested (9 ) 65.64 Forfeited (7 ) 60.85 Non-vested balance as of March 31, 2019 70 $ 81.26 Three months ended March 31, 2018 Shares (000s) Weighted Average Grant Date Fair Value Non-vested balance as of December 31, 2017 39 $ 72.62 Granted 32 71.27 Vested (15 ) 58.78 Forfeited — — Non-vested balance as of March 31, 2018 56 $ 75.47 The performance share (“PS”) awards provide the recipients the right to receive a certain number of shares of the Company’s common stock in the future, subject to an EBITDA performance hurdle, where vesting is dependent upon the Company achieving a certain EBITDA percentage growth over the performance period, and relative total shareholder return (TSR) where vesting is dependent upon the Company’s TSR performance over the performance period relative to a comparator group consisting of the Russell 2000 index constituents. Expense is measured based on the fair value at the date of grant utilizing a Black-Scholes methodology to produce a Monte-Carlo simulation model which allows for the incorporation of the performance hurdles that must be met before the PS vests. The assumptions used in the fair value determination were risk free interest rates of 2.5% and 2.4% ; dividend yields of 0.5% and 0.5% ; volatilities of 24% and 27% ; and initial TSR’s of -5.9% and -10.5% , in each case for the three months ended March 31, 2019 and 2018 , respectively. Expense is estimated based on the number of shares expected to vest, assuming the requisite service period is rendered and the probable outcome of the performance condition is achieved. The estimate is revised if subsequent information indicates that the actual number of shares likely to vest differs from previous estimates. Expense is ultimately adjusted based on the actual achievement of service and performance targets. The PS will cliff vest 100% at the end of the third year following the grant in accordance with the performance metrics set forth. As of March 31, 2019 and 2018 , there was $17,475 and $13,487 , respectively, of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the plans. As of March 31, 2019 , the unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 2 years . The Company estimates that share-based compensation expense for the year ended December 31, 2019 will be approximately $7,700 . REPURCHASE OF COMMON STOCK The Company has an approved stock repurchase program. The total authorization under this program is 3,763,083 shares. Since the inception of the program in June 1999, a total of 2,199,268 shares have been purchased, of which 6,196 shares remained in treasury at March 31, 2019 . During the three months ended March 31, 2019 and 2018 , a total of 8,496 and 10,454 shares, respectively, have been purchased at an average cost of $85.53 and $75.04

INVENTORIES

INVENTORIES	3 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories at March 31, 2019 and December 31, 2018 consisted of the following: March 31, 2019 December 31, 2018 Raw materials $ 21,398 $ 23,661 Work in progress 5,102 4,649 Finished goods 40,264 38,877 Total inventories $ 66,764 $ 67,187

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	3 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment at March 31, 2019 and December 31, 2018 are summarized as follows: March 31, 2019 December 31, 2018 Land $ 8,489 $ 7,965 Building 68,844 67,702 Equipment 201,890 213,909 Construction in progress 21,362 18,170 300,585 307,746 Less: accumulated depreciation 112,549 113,407 Property, plant and equipment, net $ 188,036 $ 194,339

INTANGIBLE ASSETS

INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	INTANGIBLE ASSETS The Company had goodwill in the amount of $446,453 and $447,995 as of March 31, 2019 and December 31, 2018 , respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.” The decrease in goodwill is primarily the result of the reclassification of a portion of the Company's goodwill to assets held for sale (See Note 2) of $1,380 , with the remaining change due to foreign exchange translation adjustments. Refer to Note 2 "Significant Acquisitions and Divestitures" for more information. Identifiable intangible assets with finite lives at March 31, 2019 and December 31, 2018 are summarized as follows: Amortization Period (in years) Gross Accumulated Gross Accumulated Customer relationships & lists 10 $ 192,120 $ 126,408 $ 192,185 $ 122,545 Trademarks & trade names 5-17 39,681 17,409 39,934 16,755 Developed technology 5 13,338 9,271 13,338 8,604 Other 3-18 14,907 6,870 14,913 6,481 $ 260,046 $ 159,958 $ 260,370 $ 154,385 Amortization of identifiable intangible assets was approximately $5,842 and $6,193 for the three months ended March 31, 2019 and 2018, respectively. Assuming no change in the gross carrying value of identifiable intangible assets, estimated amortization expense is $17,140 for the remainder of 2019 , $20,878 for 2020 , $17,645 for 2021 , $16,151 for 2022 , $14,879 for 2023 and $6,486 for 2024 . At March 31, 2019 and 2018, there were no identifiable intangible assets with indefinite useful lives as defined by ASC 350. Identifiable intangible assets are reflected in “Intangible assets with finite lives, net” in the Company’s condensed consolidated balance sheets. There were no changes to the useful lives of intangible assets subject to amortization during the three months ended March 31, 2019

EQUITY-METHOD INVESTMENT

EQUITY-METHOD INVESTMENT	3 Months Ended
	Mar. 31, 2019
Equity Method Investments and Joint Ventures [Abstract]
EQUITY-METHOD INVESTMENT	EQUITY-METHOD INVESTMENT In 2013, the Company and Eastman Chemical Company (formerly Taminco Corporation) formed a joint venture ( 66.66% / 33.34% ownership), St. Gabriel CC Company, LLC, to design, develop, and construct an expansion of the Company’s St. Gabriel aqueous choline chloride plant. The Company contributed the St. Gabriel plant, at cost, and expansion will be funded by the owners. The joint venture became operational as of July 1, 2016. St. Gabriel CC Company, LLC is a Variable Interest Entity (VIE) because the total equity at risk is not sufficient to permit the joint venture to finance its own activities without additional subordinated financial support. Additionally, voting rights ( 2 votes each) are not proportionate to the owners’ obligation to absorb expected losses or receive the expected residual returns of the joint venture. The Company will receive up to 2/3 of the production offtake capacity and absorbs operating expenses approximately proportional to the actual percentage of offtake. The joint venture is accounted for under the equity method of accounting since the Company is not the primary beneficiary as the Company does not have the power to direct the activities of the joint venture that most significantly impact its economic performance. The Company recognized a loss of $101 and $139 for the three months ended March 31, 2019 and 2018 , respectively, relating to its portion of the joint venture's expenses in other expense. The carrying value of the joint venture at March 31, 2019 and December 31, 2018 is $4,801 and $4,902 , respectively, and is recorded in other assets

REVOLVING LOAN

REVOLVING LOAN	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
REVOLVING LOAN	REVOLVING LOAN On June 27, 2018, the Company and a bank syndicate entered into a five year senior secured revolving credit agreement (“Credit Agreement”), which replaced the existing credit facility that had provided for a senior secured term loan A of $350,000 and a revolving loan of $100,000 . The Credit Agreement, which expires on June 27, 2023 , provides for revolving loans up to $500,000 (collectively referred to as the “loans”). The loans may be used for working capital, letters of credit, and other corporate purposes and may be drawn upon at the Company’s discretion. The initial proceeds from the Credit Agreement were used to repay the outstanding balance of $210,750 on its senior secured term loan A, which was due May 2019 . There are no installment payments required on the revolving loans; they may be voluntarily prepaid in whole or in part without premium or penalty, and all outstanding amounts are due on the maturity date. As of March 31, 2019 , the balance outstanding amounted to $140,000 . Amounts outstanding under the Credit Agreement are subject to an interest rate equal to a fluctuating rate as defined by the Credit Agreement plus an applicable rate. The applicable rate is based upon the Company’s consolidated net leverage ratio, as defined in the Credit Agreement, and the interest rate was 3.496% at March 31, 2019 . The Company is also required to pay a commitment fee on the unused portion of the revolving loan, which is based on the Company’s consolidated net leverage ratio as defined in the Credit Agreement and ranges from 0.15% to 0.275% ( 0.15% at March 31, 2019 ). The unused portion of the revolving loan amounted to $360,000 at March 31, 2019 . The Company is also required to pay, as applicable, letter of credit fees, administrative agent fees, and other fees to the arrangers and lenders. Costs associated with the issuance of the revolving loans are capitalized and amortized on a straight-line basis over the term of the Credit Agreement. Costs associated with the issuance of the extinguished debt instrument were capitalized and amortized over the term of the respective financing arrangement using the effective interest method. Capitalized costs net of accumulated amortization totaled $1,197 and $1,268 at March 31, 2019 and December 31, 2018, respectively, and are included in other assets on the balance sheet. Amortization expense pertaining to these costs totaled $71 and $109 for the three months ended March 31, 2019 and 2018, respectively, and are included in interest expense in the accompanying condensed consolidated statements of earnings. The Credit Agreement contains quarterly covenants requiring the consolidated leverage ratio to be less than a certain maximum ratio and the consolidated interest coverage ratio to exceed a certain minimum ratio. At March 31, 2019

NET EARNINGS PER SHARE

NET EARNINGS PER SHARE	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
NET EARNINGS PER SHARE	NET EARNINGS PER SHARE The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per share: Three months ended March 31, 2019 Net Earnings (Numerator) Number of Shares (Denominator) Per Share Amount Basic EPS – Net earnings and weighted average common shares outstanding $ 18,783 32,188,469 $ .58 Effect of dilutive securities – stock options, restricted stock, and performance shares 320,663 Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options, restricted stock, and performance shares $ 18,783 32,509,132 $ .58 Three months ended March 31, 2018 Net Earnings (Numerator) Number of Shares (Denominator) Per Share Amount Basic EPS – Net earnings and weighted average common shares outstanding $ 19,346 31,985,332 $ .60 Effect of dilutive securities – stock options, restricted stock, and performance shares 342,001 Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options, restricted stock, and performance shares $ 19,346 32,327,333 $ .60 The Company had 515,573 and 347,211 stock options outstanding at March 31, 2019 and 2018

INCOME TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company’s effective tax rate for the three months ended March 31, 2019 and 2018 , was 24.2% and 23.2% , respectively. The increase in the effective tax rate for the three months ended March 31, 2019 compared to the three months ended March 31, 2018 was attributable to higher state taxes and lower excess tax benefits from stock-based compensation. Balchem will continue to evaluate and analyze the impact of the U.S. Tax Cuts and Jobs Act that was enacted on December 22, 2017 and the additional guidance that has been issued, and may be issued, by the U.S. Department of Treasury, the Securities and Exchange Commission, or the Financial Accounting Standards Board regarding this act. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company regularly reviews its deferred tax assets for recoverability and would establish a valuation allowance if it believed that such assets may not be recovered, taking into consideration historical operating results, expectations of future earnings, changes in its operations and the expected timing of the reversals of existing temporary differences. The Company accounts for uncertainty in income taxes utilizing ASC 740-10, "Income Taxes". ASC 740-10 clarifies whether or not to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. It prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken or expected to be taken. This interpretation also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, and disclosures. The application of ASC 740-10 requires judgment related to the uncertainty in income taxes and could impact our effective tax rate. The Company files income tax returns in the U.S. and in various states and foreign countries. As of March 31, 2019 , in the major jurisdictions where the Company operates, it is generally no longer subject to income tax examinations by tax authorities for years before 2014. As of March 31, 2019 and December 31, 2018 , the Company had approximately $5,648 and $5,709 , respectively, of unrecognized tax benefits, which are included in other long-term obligations on the Company’s consolidated balance sheets. The Company includes interest expense or income as well as potential penalties on unrecognized tax positions as a component of income tax expense in the consolidated statements of earnings. The total amount of accrued interest and penalties related to uncertain tax positions at March 31, 2019 and December 31, 2018 was approximately $1,854 and $1,839

SEGMENT INFORMATION

SEGMENT INFORMATION	3 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION Human Nutrition & Health The Company's Human Nutrition & Health ("HNH") segment provides human grade choline nutrients and mineral amino acid chelated products through this segment for wellness applications. Choline is recognized to play a key role in the development and structural integrity of brain cell membranes in infants, processing dietary fat, reproductive development and neural functions, such as memory and muscle function. The Company's mineral amino acid chelates, specialized mineral salts, and mineral complexes are used as raw materials for inclusion in premier human nutrition products. Proprietary technology has been combined to create an organic molecule in a form the body can readily assimilate. Sales growth for human nutrition applications is reliant on differentiation from lower-cost competitive products through scientific data, intellectual property and customer perceptions of brand value. Consequently, the Company makes investments in such activities for long-term value differentiation. This segment also serves the food and beverage industry for beverage, bakery, dairy, confectionary, and savory manufacturers. The Company partners with our customers from ideation through commercialization to bring on-trend beverages, baked goods, confections, dairy and meat products to market. The Company's expertise in trends analysis and product development, combined with manufacturing capabilities in customized spray dried and emulsified powders, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, as well as ice cream bases and variegates makes the Company a one-stop solutions provider for beverage and dairy product development needs. Additionally, this segment provides microencapsulation solutions to a variety of applications in food, pharmaceutical and nutritional ingredients to enhance performance of nutritional fortification, processing, mixing, and packaging applications and shelf-life. Major product applications are baked goods, refrigerated and frozen dough systems, processed meats, seasoning blends, confections, and nutritional supplements. The Company also creates cereal systems for ready-to-eat cereals, grain-based snacks, and cereal based ingredients. Animal Nutrition & Health The Company’s Animal Nutrition & Health (“ANH”) segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to basic choline chloride. For ruminant animals, the Company’s microencapsulated products boost health and milk production, delivering nutrient supplements that are biologically available, providing required nutritional levels. The Company’s proprietary chelation technology provides enhanced nutrient absorption for various species of production and companion animals and is marketed for use in animal feed throughout the world. ANH also manufactures and supplies choline chloride, an essential nutrient for monogastric animal health, predominantly to the poultry, pet and swine industries. Choline, which is manufactured and sold in both dry and aqueous forms, plays a vital role in the metabolism of fat. In poultry, choline deficiency can result in reduced growth rates and perosis in young birds, while in swine production choline is a necessary and required component of gestating and lactating sow diets for both liver health and prevention of leg deformity. Sales of value-added encapsulated products are highly dependent on overall industry economics as well as the Company's ability to leverage the results of university and field research on the animal health and production benefits of our products. Management believes that success in the commodity-oriented basic choline chloride marketplace is highly dependent on the Company’s ability to maintain its strong reputation for excellent product quality and customer service. The Company continues to drive production efficiencies in order to maintain its competitive-cost position to effectively compete in a competitive global marketplace. Specialty Products Ethylene oxide, at the 100% level, is sold as a sterilant gas, primarily for use in the health care industry. It is used to sterilize a wide range of medical devices because of its versatility and effectiveness in treating hard or soft surfaces, composites, metals, tubing and different types of plastics without negatively impacting the performance of the device being sterilized. The Company’s 100% ethylene oxide product is distributed in uniquely designed, recyclable, double-walled, stainless steel drums to assure compliance with safety, quality and environmental standards as outlined by the EPA and the DOT. The Company’s inventory of these specially built drums, along with its two filling facilities, represents a significant capital investment. Contract sterilizers and medical device manufacturers are principal customers for this product. The Company also sells single use canisters with 100% ethylene oxide for use in sterilizing re-usable devices typically processed in autoclave units in hospitals. As a fumigant, ethylene oxide blends are highly effective in killing bacteria, fungi, and insects in spices and other seasoning materials. Propylene oxide is marketed and sold as a fumigant to aid in the control of insects and microbiological spoilage; and to reduce bacterial and mold contamination in certain shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs and prunes. The Company distributes its propylene oxide product primarily in recyclable, single-walled, carbon steel cylinders according to standards outlined by the EPA and the DOT. Its inventory of these cylinders also represents a significant capital investment. Propylene oxide is also sold to customers seeking smaller (as opposed to bulk) quantities and whose requirements include utilization in various chemical synthesis applications, such as increasing paint durability and manufacturing specialty starches and textile coatings. The Company’s micronutrient agricultural nutrition business sells chelated minerals primarily into high value crops. The Company has a unique and patented two-step approach to solving mineral deficiency in plants to optimize health, yield and shelf-life. First, the Company determines optimal mineral balance for plant health. The Company then has a foliar applied Metalosate product range, utilizing patented amino acid chelate technology. Its products quickly and efficiently deliver mineral nutrients. As a result, the farmer/grower gets healthier crops that are more resistant to disease and pests, larger yields and healthier food for the consumer with extended shelf life for produce being shipped long distances. Industrial Products Certain derivatives of choline chloride are manufactured and sold into industrial applications predominately as a component for hydraulic fracturing of shale natural gas wells. The Company’s products offer an attractive, effective and more environmentally responsible alternative than other clay stabilizers. Industrial grade choline bicarbonate is completely chloride free and the Company's choline chloride reduces the amount of chlorides released into the environment up to 75% when compared to potassium chloride. The Industrial Products segment also includes the manufacture and sale of methylamines. Methylamines are a primary building block for the manufacture of choline products and are produced at its Italian operation and sold for a wide range of industrial applications in Europe. The segment information is summarized as follows: Business Segment Assets: March 31, December 31, Human Nutrition & Health $ 703,042 $ 702,692 Animal Nutrition & Health 135,738 136,810 Specialty Products 65,715 59,558 Industrial Products 25,588 22,822 Other Unallocated (1) 41,805 59,473 Total $ 971,888 $ 981,355 (1) Other unallocated assets consist of certain cash, receivables, prepaid expenses, equipment and leasehold improvements, net of accumulated depreciation, and deferred income taxes, which the Company does not allocate to its individual business segments. Business Segment Net Sales: Three Months Ended 2019 2018 Human Nutrition & Health $ 85,149 $ 83,063 Animal Nutrition & Health 43,361 46,141 Specialty Products 18,424 17,740 Industrial Products 10,095 14,466 Total $ 157,029 $ 161,410 Business Segment Earnings Before Income Taxes: Three Months Ended 2019 2018 Human Nutrition & Health $ 13,703 $ 12,932 Animal Nutrition & Health 5,256 7,484 Specialty Products 6,697 5,034 Industrial Products 1,637 2,479 Transaction costs, integration costs, and unallocated legal fees (2) (804 ) (689 ) Unallocated amortization expense (3) (9 ) — Interest and other (expense) (1,687 ) (2,063 ) Total $ 24,793 $ 25,177 (2) Transaction costs, integration costs and unallocated legal fees for three month ended March 31, 2019 and 2018, respectively, were primarily related to acquisitions. (3) Unallocated amortization expense for three months ended March 31, 2019 was related to amortization of intangible assets in connection with a company-wide ERP system implementation. Depreciation/Amortization: Three Months Ended 2019 2018 Human Nutrition & Health $ 7,986 $ 8,532 Animal Nutrition & Health 1,578 1,305 Specialty Products 1,021 1,010 Industrial Products 171 171 Total $ 10,756 $ 11,018 Capital Expenditures : Three Months Ended 2019 2018 Human Nutrition & Health $ 5,255 $ 2,079 Animal Nutrition & Health 1,471 830 Specialty Products 1,474 582 Industrial Products 288 244 Total $ 8,488 $ 3,735

REVENUE

REVENUE	3 Months Ended
	Mar. 31, 2019
Revenue from Contract with Customer [Abstract]
REVENUE	REVENUE Revenue Recognition Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration the Company expects to realize in exchange for those goods. The following table presents revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues. Three Months Ended 2019 2018 Product Sales $ 143,874 $ 146,914 Co-manufacturing 10,630 10,707 Bill and Hold 857 1,289 Consignment 589 1,045 Product Sales Revenue 155,950 159,955 Royalty Revenue 1,079 1,455 Total Revenue $ 157,029 $ 161,410 The following table presents revenues disaggregated by geography, based on the billing addresses of customers: Three Months Ended 2019 2018 United States $ 118,111 $ 120,668 Foreign Countries 38,918 40,742 Total Revenue $ 157,029 $ 161,410 Product Sales Revenues The Company’s primary operation is the manufacturing and sale of health and wellness ingredient products, in which the Company receives an order from a customer and fulfills that order. The Company’s product sales have four sub-streams of revenue: product sales, co-manufacturing, bill and hold, and consignment. Under the co-manufacturing agreements, the Company is responsible for the manufacture of a finished good where the customer provides some or all of the raw materials. The Company controls the manufacturing process and the ultimate end-product before it is shipped to the customer. Based on these factors, the Company has determined that it is the principal in these agreements and therefore revenue is recognized in the gross amount of consideration the Company expects to be entitled for the goods provided. Royalty Revenues Royalty revenue consists of agreements with customers to use the Company’s intellectual property in exchange for a sales-based royalty. Royalty revenue is recorded as part of the Human Nutrition & Health segment. Contract Liabilities The Company records contract liabilities when cash payments are received or due in advance of performance, including amounts which are refundable. The Company’s payment terms vary by the type and location of customers and the products offered. The term between invoicing and when payment is due is not significant. For certain products or services and customer types, the Company requires payment before the products are delivered to the customer. Practical Expedients and Exemptions The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling and marketing expenses.

SUPPLEMENTAL CASH FLOW INFORMAT

SUPPLEMENTAL CASH FLOW INFORMATION	3 Months Ended
	Mar. 31, 2019
Supplemental Cash Flow Information [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	SUPPLEMENTAL CASH FLOW INFORMATION Cash paid during the three months ended March 31, 2019 and 2018 for income taxes and interest is as follows: Three Months Ended 2019 2018 Income taxes $ 58 $ — Interest $ 1,459 $ 1,763

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	3 Months Ended
	Mar. 31, 2019
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) The changes in accumulated other comprehensive (loss)/income were as follows: Three Months Ended 2019 2018 Net foreign currency translation adjustment $ (1,089 ) $ 1,363 Net change in postretirement benefit plan (see Note 15 for further information) Amortization of prior service cost 18 18 Amortization of gain (11 ) (1 ) Total before tax 7 17 Tax (2 ) (4 ) Net of tax 5 13 Total other comprehensive (loss)/income $ (1,084 ) $ 1,376 Accumulated other comprehensive loss at March 31, 2019 and December 31, 2018 consisted of the following: Foreign currency translation adjustment Postretirement benefit plan Total Balance December 31, 2018 $ (4,285 ) $ 683 $ (3,602 ) Other comprehensive (loss)/income (1,089 ) 5 (1,084 ) Balance March 31, 2019 $ (5,374 ) $ 688 $ (4,686 )

EMPLOYEE BENEFIT PLANS

EMPLOYEE BENEFIT PLANS	3 Months Ended
	Mar. 31, 2019
Retirement Benefits [Abstract]
EMPLOYEE BENEFIT PLANS	EMPLOYEE BENEFIT PLANS The Company provides postretirement benefits in the form of two unfunded postretirement medical plans; one that under a collective bargaining agreement covers eligible retired employees of the Verona facility and a plan for those named as executive officers in the Company’s proxy statement . Net periodic benefit costs for such retirement medical plans were as follows: Three Months Ended 2019 2018 Service cost $ 16 $ 19 Interest cost 10 11 Amortization of prior service cost 18 18 Amortization of gain (11 ) (1 ) Net periodic benefit cost $ 33 $ 47 The amount recorded for these obligations on the Company’s balance sheet as of March 31, 2019 and December 31, 2018 is $1,200 and $1,174 , respectively, and is included in other long-term obligations. These plans are unfunded and approved claims are paid from Company funds. Historical cash payments made under such plan have typically been less than $100 per year. On June 1, 2018, the Company established an unfunded, nonqualified deferred compensation plan maintained for the benefit of a select group of management or highly compensated employees. Assets of the plan are held in a rabbi trust, which are subject to additional risk of loss in the event of bankruptcy or insolvency of the Company. The deferred compensation liability was $1,513 and $265 as of March 31, 2019 and December 31, 2018, respectively, and is included in other long-term obligations on the Company’s balance sheet. The related rabbi trust assets were $1,513 and $265

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Rent expense charged to operations under lease agreements for the three months ended March 31, 2019 and 2018 aggregated approximately $813 and $786 , respectively. Aggregate future minimum rental payments required under all non-cancelable operating leases at March 31, 2019 are as follows: Year April 1, 2019 to December 31, 2019 $ 2,562 2020 2,912 2021 2,005 2022 1,415 2023 1,176 2024 1,024 Thereafter 3,594 Total minimum lease payments $ 14,688 The Company’s Verona, Missouri facility, while held by a prior owner, was designated by the EPA as a Superfund site and placed on the National Priorities List in 1983, because of dioxin contamination on portions of the site. Remediation was conducted by the prior owner under the oversight of the EPA and the Missouri Department of Natural Resources (“MDNR”). While the Company must maintain the integrity of the capped areas in the remediation areas on the site, the prior owner is responsible for completion of any further Superfund remedy. The Company is indemnified by the sellers under its May 2001 asset purchase agreement covering its acquisition of the Verona, Missouri facility for potential liabilities associated with the Superfund site.

FAIR VALUE OF FINANCIAL INSTRUM

FAIR VALUE OF FINANCIAL INSTRUMENTS	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	FAIR VALUE OF FINANCIAL INSTRUMENTS The Company has a number of financial instruments, none of which are held for trading purposes. The Company estimates that the fair value of all financial instruments at March 31, 2019 and December 31, 2018 does not differ materially from the aggregate carrying values of its financial instruments recorded in the accompanying condensed consolidated balance sheets. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is necessarily required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio. The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable, and accrued liabilities, which are carried at cost and approximate fair value due to the short-term maturity of these instruments. Cash and cash equivalents at March 31, 2019 and December 31, 2018 includes $797 and $793 in money market funds, respectively. Non-current assets at March 31, 2019 and December 31, 2018 includes $1,513 and $265

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS The Company provides services on a contractual agreement to St. Gabriel CC Company, LLC. These services include accounting, information technology, quality control, and purchasing services, as well as operation of the St. Gabriel CC Company, LLC plant. The Company also sells raw materials to St. Gabriel CC Company, LLC. These raw materials are used in the production of finished goods that are, in turn, sold by Saint Gabriel CC Company, LLC to the Company for resale to unrelated parties. As such, the sale of these raw materials to St. Gabriel CC Company, LLC in this scenario lacks economic substance and therefore the Company does not include them in net sales within the consolidated statement of earnings. The services the Company provided amounted to $868 and $927 , respectively, for the three months ended March 31, 2019 and 2018 . The raw materials sold amounted to $6,808 and $7,278 , respectively, for the three months ended March 31, 2019 and 2018 . These services and raw materials are primarily recorded in cost of goods sold net of the finished goods received from St. Gabriel CC Company, LLC of $5,312 and $6,036 , respectively, for the three months ended March 31, 2019 and 2018 . At March 31, 2019 and December 31, 2018, the Company had receivables of $4,897 and $3,210 , respectively, recorded in accounts receivable from St. Gabriel CC Company, LLC for services rendered and raw materials sold and payables of $1,567 and $1,943 , respectively, for finished goods received recorded in accrued expenses. In addition, the Company had payables in the amount of $310 and $314 , respectively, related to non-contractual monies owed to St. Gabriel CC Company, LLC, recorded in accrued expenses as of March 31, 2019 and December 31, 2018

LEASES

LEASES	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
LEASES	LEASES The Company has both real estate leases and equipment leases. The main types of equipment leases include forklifts, trailers, printers and copiers, railcars, and trucks. All leases are categorized as operating leases. As a result of electing the practical expedient, variable lease payments are combined and recognized on the balance sheet in the event that those charges and any related increases are explicitly stated in the lease. Such payments include common area maintenance charges, property taxes, and insurance charges and are recorded in the ROU asset and corresponding liability when the payments are stated in the lease with (a) fixed or in-substance fixed amounts, or (b) a variable payment based on an index or rate. Due to the acquisitive nature of the Company and the potential for synergies upon integration of acquired entities, the Company determined that the reasonably certain criterion could not be met for any renewal periods beginning two years beyond the implementation date, which is January 1, 2019. In addition, the Company has historically not been exercising purchase options with equipment leases as it does not make economic sense to buy the equipment. Instead, the Company has historically replaced the equipment with a new lease. Therefore, the Company determined that the reasonably certain criterion could not be met as it relates to purchase options. The Company has no residual value guarantees in lease transactions. The Company did not identify any embedded leases. As indicated above, the Company elected the practical expedient to combine lease and non-lease components and recognizes the combined amount on the consolidated balance sheet. Management determined that since the Company has a centralized treasury function, the parent company would either fund or guarantee a subsidiary's loan for borrowing over a similar term. As such, the Company's management determined it is appropriate to utilize a corporate based borrowing rate for all locations. The Company developed four tranches of leases based on lease terms and these tranches reflect the composition of the current lease portfolio. The Company's borrowing history shows that interest rates of a term loan or a line of credit depend on the duration of the loan rather than the nature of the assets purchased by those funds. Based on this understanding, the Company elected to use a portfolio approach to discount rate, applying corporate rates to the tranches of leases based on lease terms. Based on the Company's risk rating, the company applied the following discount rates upon implementation: (1) 1-2 years, 3.45% (2) 3-4 years, 4.04% (3) 5-9 years, 4.38% and (4) 10+ years, 5.10% . For the three months ended March 31, 2019, the Company's total lease cost is as follows, which includes both amounts recognized in profits or losses during the period and amounts capitalized on the balance sheet, and the cash flows arising from lease transactions: Three Months Ended March 31, 2019 Lease Cost Operating lease cost 813 Other information (Gains) and losses on sale and leaseback transactions, net — Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases 819 Right-of-use assets obtained in exchange for new operating lease liabilities 12,874 Weighted-average remaining lease term - operating leases 4.88 years Weighted-average discount rate - operating 4.5 %

CONDENSED CONSOLIDATED FINANC_2

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Policies)	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Issued Accounting Standards In March 2019, the FASB issued ASU 2019-01, "Leases (Topic 842): Codification Improvements," which further clarifies the determination of fair value of leases and modifies transition disclosure requirements for changes in accounting principles. The effective date of the amendments is for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company is currently evaluating the impact of this pronouncement on the Company’s consolidated financial statements and disclosures. As stated below, the Company adopted Accounting Standards Codification ("ASC") 842 ("ASU 2016-02), Leases, as of January 1, 2019. In August 2018, the FASB issued ASU 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.” The guidance requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the noncancelable term of the cloud computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2) for which exercise of the renewal option is controlled by the cloud service provider. The effective date of this pronouncement is for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted and the standard may be adopted either using the prospective or retrospective transition approach. The Company is currently evaluating the impact of this pronouncement on the Company’s consolidated financial statements and disclosures. In August 2018, the FASB issued ASU 2018-14, “Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans,” which modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement benefit plans. The guidance removes disclosures that are no longer considered cost beneficial, clarifies the specific requirements of disclosures and adds disclosure requirements identified as relevant. This update should be applied on a retrospective basis to all periods presented and is effective for fiscal years ending after December 31, 2020. Early adoption is permitted. The Company expects this new guidance will have minimal impact on its financial reporting. In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment” (ASU 2017-04), which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. The guidance is effective for annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted; however, the Company has elected not to adopt early as this ASU will not have a significant impact on the Company’s consolidated financial statements. Recently Adopted Accounting Standards In February 2016, the FASB issued ASU No. 2016-02, “Leases” (“ASU 2016-02”), which was clarified by ASU 2018-11 and addresses the recognition of assets and liabilities that arise from all leases. The guidance requires lessees to recognize right-of-use assets

SIGNIFICANT ACQUISITIONS AND _2

SIGNIFICANT ACQUISITIONS AND DIVESTITURES (Tables)	3 Months Ended
	Mar. 31, 2019
Business Combinations [Abstract]
Schedule of Assets and Liabilities Held for Sale	The related assets and liabilities have been reclassified as current assets held for sale and current liabilities held for sale within the Company's condensed consolidated balance sheets as of March 31, 2019 and include the following: March 31, 2019 Accounts receivable $ 353 Inventory 376 Property, plant, and equipment, net 9,314 Right of use assets 317 Goodwill 1,380 Other current assets 8 Assets held for sale $ 11,748 Trade accounts payable $ 126 Accrued expenses 260 Accrued compensation and other benefits 52 Lease liabilities 319 Liabilities held for sale $ 757

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	3 Months Ended
	Mar. 31, 2019
Stockholders' Equity Note [Abstract]
Schedule of Compensation Cost on Net Earnings	The Company’s results for the three months ended March 31, 2019 and 2018 reflected the following stock-based compensation cost, and such compensation cost had the following effects on net earnings: Increase/(Decrease) for the 2019 2018 Cost of sales $ 288 $ 245 Operating expenses 1,343 1,548 Net earnings (1,258 ) (1,378 )
Schedule of Stock Option Activity	Option activity for the three months ended March 31, 2019 and 2018 is summarized below: Shares (000s) Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Term Outstanding as of December 31, 2018 887 $ 61.59 $ 16,192 Granted 185 84.19 Exercised (7 ) 40.85 Forfeited — — Canceled — — Outstanding as of March 31, 2019 1,065 $ 65.64 $ 28,924 6.7 Exercisable as of March 31, 2019 685 $ 56.91 $ 24,588 5.4 Shares (000s) Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Term Outstanding as of December 31, 2017 946 $ 55.44 $ 24,714 Granted 148 74.57 Exercised (39 ) 32.83 Forfeited (1 ) 73.49 Canceled (1 ) 25.39 Outstanding as of March 31, 2018 1,053 $ 58.98 $ 24,680 6.6 Exercisable as of March 31, 2018 637 $ 48.54 $ 21,306 5.3
Schedule of Other Information Pertaining to Stock Option Activity	Other information pertaining to option activity during the three months ended March 31, 2019 and 2018 was as follows: Three Months Ended March 31, 2019 2018 Weighted-average fair value of options granted $ 18.26 $ 18.62 Total intrinsic value of stock options exercised ($000s) $ 302 $ 1,825
Schedule of Non-vested Restricted Stock Activity	Non-vested restricted stock activity for the three months ended March 31, 2019 and 2018 is summarized below: Three months ended March 31, 2019 Shares (000s) Weighted Average Grant Date Fair Value Non-vested balance as of December 31, 2018 79 $ 72.75 Granted 66 84.27 Vested (8 ) 58.52 Forfeited — — Non-vested balance as of March 31, 2019 137 $ 79.16 Three months ended March 31, 2018 Shares (000s) Weighted Average Grant Date Fair Value Non-vested balance as of December 31, 2017 66 $ 65.66 Granted 36 74.57 Vested (6 ) 50.32 Forfeited — — Non-vested balance as of March 31, 2018 96 $ 70.10
Schedule of Non-vested Performance Share Activity	Non-vested performance share activity for the three months ended March 31, 2019 and 2018 is summarized below: Three months ended March 31, 2019 Shares (000s) Weighted Average Grant Date Fair Value Non-vested balance as of December 31, 2018 53 $ 75.61 Granted 33 81.79 Vested (9 ) 65.64 Forfeited (7 ) 60.85 Non-vested balance as of March 31, 2019 70 $ 81.26 Three months ended March 31, 2018 Shares (000s) Weighted Average Grant Date Fair Value Non-vested balance as of December 31, 2017 39 $ 72.62 Granted 32 71.27 Vested (15 ) 58.78 Forfeited — — Non-vested balance as of March 31, 2018 56 $ 75.47

INVENTORIES (Tables)

INVENTORIES (Tables)	3 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories at March 31, 2019 and December 31, 2018 consisted of the following: March 31, 2019 December 31, 2018 Raw materials $ 21,398 $ 23,661 Work in progress 5,102 4,649 Finished goods 40,264 38,877 Total inventories $ 66,764 $ 67,187

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	3 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment at March 31, 2019 and December 31, 2018 are summarized as follows: March 31, 2019 December 31, 2018 Land $ 8,489 $ 7,965 Building 68,844 67,702 Equipment 201,890 213,909 Construction in progress 21,362 18,170 300,585 307,746 Less: accumulated depreciation 112,549 113,407 Property, plant and equipment, net $ 188,036 $ 194,339

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Identifiable Intangible Assets	Identifiable intangible assets with finite lives at March 31, 2019 and December 31, 2018 are summarized as follows: Amortization Period (in years) Gross Accumulated Gross Accumulated Customer relationships & lists 10 $ 192,120 $ 126,408 $ 192,185 $ 122,545 Trademarks & trade names 5-17 39,681 17,409 39,934 16,755 Developed technology 5 13,338 9,271 13,338 8,604 Other 3-18 14,907 6,870 14,913 6,481 $ 260,046 $ 159,958 $ 260,370 $ 154,385

NET EARNINGS PER SHARE (Tables)

NET EARNINGS PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Reconciliation of the Net Earnings and Shares Used in Calculating Basic and Diluted Net Earnings Per Share	The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per share: Three months ended March 31, 2019 Net Earnings (Numerator) Number of Shares (Denominator) Per Share Amount Basic EPS – Net earnings and weighted average common shares outstanding $ 18,783 32,188,469 $ .58 Effect of dilutive securities – stock options, restricted stock, and performance shares 320,663 Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options, restricted stock, and performance shares $ 18,783 32,509,132 $ .58 Three months ended March 31, 2018 Net Earnings (Numerator) Number of Shares (Denominator) Per Share Amount Basic EPS – Net earnings and weighted average common shares outstanding $ 19,346 31,985,332 $ .60 Effect of dilutive securities – stock options, restricted stock, and performance shares 342,001 Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options, restricted stock, and performance shares $ 19,346 32,327,333 $ .60

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	The segment information is summarized as follows: Business Segment Assets: March 31, December 31, Human Nutrition & Health $ 703,042 $ 702,692 Animal Nutrition & Health 135,738 136,810 Specialty Products 65,715 59,558 Industrial Products 25,588 22,822 Other Unallocated (1) 41,805 59,473 Total $ 971,888 $ 981,355 (1) Other unallocated assets consist of certain cash, receivables, prepaid expenses, equipment and leasehold improvements, net of accumulated depreciation, and deferred income taxes, which the Company does not allocate to its individual business segments. Business Segment Net Sales: Three Months Ended 2019 2018 Human Nutrition & Health $ 85,149 $ 83,063 Animal Nutrition & Health 43,361 46,141 Specialty Products 18,424 17,740 Industrial Products 10,095 14,466 Total $ 157,029 $ 161,410 Business Segment Earnings Before Income Taxes: Three Months Ended 2019 2018 Human Nutrition & Health $ 13,703 $ 12,932 Animal Nutrition & Health 5,256 7,484 Specialty Products 6,697 5,034 Industrial Products 1,637 2,479 Transaction costs, integration costs, and unallocated legal fees (2) (804 ) (689 ) Unallocated amortization expense (3) (9 ) — Interest and other (expense) (1,687 ) (2,063 ) Total $ 24,793 $ 25,177 (2) Transaction costs, integration costs and unallocated legal fees for three month ended March 31, 2019 and 2018, respectively, were primarily related to acquisitions. (3) Unallocated amortization expense for three months ended March 31, 2019 was related to amortization of intangible assets in connection with a company-wide ERP system implementation. Depreciation/Amortization: Three Months Ended 2019 2018 Human Nutrition & Health $ 7,986 $ 8,532 Animal Nutrition & Health 1,578 1,305 Specialty Products 1,021 1,010 Industrial Products 171 171 Total $ 10,756 $ 11,018 Capital Expenditures : Three Months Ended 2019 2018 Human Nutrition & Health $ 5,255 $ 2,079 Animal Nutrition & Health 1,471 830 Specialty Products 1,474 582 Industrial Products 288 244 Total $ 8,488 $ 3,735

REVENUE (Tables)

REVENUE (Tables)	3 Months Ended
	Mar. 31, 2019
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenues	The following table presents revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues. Three Months Ended 2019 2018 Product Sales $ 143,874 $ 146,914 Co-manufacturing 10,630 10,707 Bill and Hold 857 1,289 Consignment 589 1,045 Product Sales Revenue 155,950 159,955 Royalty Revenue 1,079 1,455 Total Revenue $ 157,029 $ 161,410 The following table presents revenues disaggregated by geography, based on the billing addresses of customers: Three Months Ended 2019 2018 United States $ 118,111 $ 120,668 Foreign Countries 38,918 40,742 Total Revenue $ 157,029 $ 161,410

SUPPLEMENTAL CASH FLOW INFORM_2

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2019
Supplemental Cash Flow Information [Abstract]
Schedule of Supplemental Cash Flow Information	Cash paid during the three months ended March 31, 2019 and 2018 for income taxes and interest is as follows: Three Months Ended 2019 2018 Income taxes $ 58 $ — Interest $ 1,459 $ 1,763

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)	3 Months Ended
	Mar. 31, 2019
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Changes in Accumulated Other Comprehensive Income (Loss)	The changes in accumulated other comprehensive (loss)/income were as follows: Three Months Ended 2019 2018 Net foreign currency translation adjustment $ (1,089 ) $ 1,363 Net change in postretirement benefit plan (see Note 15 for further information) Amortization of prior service cost 18 18 Amortization of gain (11 ) (1 ) Total before tax 7 17 Tax (2 ) (4 ) Net of tax 5 13 Total other comprehensive (loss)/income $ (1,084 ) $ 1,376
Schedule of Accumulated Other Comprehensive Income (Loss)	Accumulated other comprehensive loss at March 31, 2019 and December 31, 2018 consisted of the following: Foreign currency translation adjustment Postretirement benefit plan Total Balance December 31, 2018 $ (4,285 ) $ 683 $ (3,602 ) Other comprehensive (loss)/income (1,089 ) 5 (1,084 ) Balance March 31, 2019 $ (5,374 ) $ 688 $ (4,686 )

EMPLOYEE BENEFIT PLANS (Tables)

EMPLOYEE BENEFIT PLANS (Tables)	3 Months Ended
	Mar. 31, 2019
Retirement Benefits [Abstract]
Schedule of Net Periodic Benefit Cost	Net periodic benefit costs for such retirement medical plans were as follows: Three Months Ended 2019 2018 Service cost $ 16 $ 19 Interest cost 10 11 Amortization of prior service cost 18 18 Amortization of gain (11 ) (1 ) Net periodic benefit cost $ 33 $ 47

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Aggregate Future Minimum Rental Payments Required under Non-Cancelable Operating Leases	Aggregate future minimum rental payments required under all non-cancelable operating leases at March 31, 2019 are as follows: Year April 1, 2019 to December 31, 2019 $ 2,562 2020 2,912 2021 2,005 2022 1,415 2023 1,176 2024 1,024 Thereafter 3,594 Total minimum lease payments $ 14,688

LEASES (Tables)

LEASES (Tables)	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Schedule of Lease Cost	For the three months ended March 31, 2019, the Company's total lease cost is as follows, which includes both amounts recognized in profits or losses during the period and amounts capitalized on the balance sheet, and the cash flows arising from lease transactions: Three Months Ended March 31, 2019 Lease Cost Operating lease cost 813 Other information (Gains) and losses on sale and leaseback transactions, net — Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases 819 Right-of-use assets obtained in exchange for new operating lease liabilities 12,874 Weighted-average remaining lease term - operating leases 4.88 years Weighted-average discount rate - operating 4.5 %

SIGNIFICANT ACQUISITIONS AND _3

SIGNIFICANT ACQUISITIONS AND DIVESTITURES - Narrative (Details) € in Thousands, $ in Thousands	May 02, 2019EUR (€)Country	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)
Business Combinations [Abstract]
Transaction and integration costs related to acquisitions		$ 485	$ 689
Chemogas
Business Acquisition [Line Items]
Transaction costs		$ 307
Chemogas | Subsequent Event
Business Acquisition [Line Items]
Purchase price | €	€ 95,000
Chemogas | Subsequent Event
Business Acquisition [Line Items]
Number of Countries in which Entity Operates | Country	70

SIGNIFICANT ACQUISITIONS AND _4

SIGNIFICANT ACQUISITIONS AND DIVESTITURES - Assets and Liabilities Held for Sale (Details) - Discontinued Operations, Held-for-sale, Not Discontinued Operations - Human Nutrition & Health $ in Thousands	Mar. 31, 2019USD ($)
Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]
Accounts receivable	$ 353
Inventory	376
Property, plant, and equipment, net	9,314
Right of use assets	317
Goodwill	1,380
Other current assets	8
Assets held for sale	11,748
Disposal Group, Including Discontinued Operation, Liabilities [Abstract]
Trade accounts payable	126
Accrued expenses	260
Accrued compensation and other benefits	52
Lease liabilities	319
Liabilities held for sale	$ 757

STOCKHOLDERS' EQUITY - Stock-Ba

STOCKHOLDERS' EQUITY - Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Impact of stock-based compensation cost on net earnings	$ (1,258)	$ (1,378)
Expiration period of options granted	10 years
Shares available for future awards (in shares)	1,096,274
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period	3 years
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period	3 years
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation cost	$ 288	245
Operating expenses
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation cost	$ 1,343	$ 1,548
Minimum | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period	3 years
Minimum | Restricted Stock | Non-Employee Director
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period	3 years
Maximum | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period	4 years
Maximum | Restricted Stock | Non-Employee Director
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period	4 years

STOCKHOLDERS' EQUITY - Stock Op

STOCKHOLDERS' EQUITY - Stock Options (Details) - Stock Options - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period (in shares)	887	946
Granted (in shares)	185	148
Exercised (in shares)	(7)	(39)
Forfeited (in shares)	0	(1)
Canceled (in shares)	0	(1)
Outstanding at end of period (in shares)	1,065	1,053
Exercisable at end of period (in shares)	685	637
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding at beginning of period (in dollars per share)	$ 61.59	$ 55.44
Granted (in dollars per share)	84.19	74.57
Exercised (in dollars per share)	40.85	32.83
Forfeited (in dollars per share)	0	73.49
Canceled (in dollars per share)	0	25.39
Outstanding at end of period (in dollars per share)	65.64	58.98
Exercisable at end of period	$ 56.91	$ 48.54
Aggregate intrinsic value, outstanding, beginning of period	$ 16,192	$ 24,714
Aggregate intrinsic value, outstanding, end of period	28,924	24,680
Aggregate intrinsic value, exercisable, end of period	$ 24,588	$ 21,306
Weighted average remaining contractual term, outstanding	6 years 8 months 12 days	6 years 7 months 6 days
Weighted average remaining contractual term, exercisable	5 years 4 months 24 days	5 years 3 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Dividend yield rate	0.60%	0.60%
Expected volatility rate	24.00%	27.00%
Risk-free interest rate	2.50%	2.60%
Expected term	4 years	4 years 4 months 24 days
Weighted-average fair value of options granted	$ 18.26	$ 18.62
Total intrinsic value of stock options exercised	$ 302	$ 1,825

STOCKHOLDERS' EQUITY - Restrict

STOCKHOLDERS' EQUITY - Restricted Stock and Performance Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Unrecognized compensation cost	$ 17,475	$ 13,487
Period for unrecognized compensation cost to be recognized over	2 years
Estimated share-based compensation expense	$ 7,700
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested balance as of beginning of period (in shares)	79	66
Granted (in shares)	66	36
Vested (in shares)	(8)	(6)
Forfeited (in shares)	0	0
Non-vested balance as of end of period (in shares)	137	96
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Non-vested balance as of beginning of period (in dollars per share)	$ 72.75	$ 65.66
Granted (in dollars per share)	84.27	74.57
Vested (in dollars per share)	58.52	50.32
Forfeited (in dollars per share)	0	0
Non-vested balance as of end of period (in dollars per share)	$ 79.16	$ 70.10
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested balance as of beginning of period (in shares)	53	39
Granted (in shares)	33	32
Vested (in shares)	(9)	(15)
Forfeited (in shares)	(7)	0
Non-vested balance as of end of period (in shares)	70	56
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Non-vested balance as of beginning of period (in dollars per share)	$ 75.61	$ 72.62
Granted (in dollars per share)	81.79	71.27
Vested (in dollars per share)	65.64	58.78
Forfeited (in dollars per share)	60.85	0
Non-vested balance as of end of period (in dollars per share)	$ 81.26	$ 75.47
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rate	2.50%	2.40%
Dividend yield rate	0.50%	0.50%
Expected volatility rate	24.00%	27.00%
Initial TSR	(5.90%)	(10.50%)
Cliff vest	100.00%

STOCKHOLDERS' EQUITY - Repurcha

STOCKHOLDERS' EQUITY - Repurchase of Common Stock (Details) - $ / shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Stockholders' Equity Note [Abstract]
Number of shares authorized to be repurchased (in shares)	3,763,083
Aggregate number of shares repurchased since inception (in shares)	2,199,268
Number of shares remaining in treasury (in shares)	6,196		706
Number of shares acquired under stock repurchase plan and subsequently reissued (in shares)	8,496	10,454
Treasury stock acquired, average cost (in dollars per share)	$ 85.53	$ 75.04

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 21,398	$ 23,661
Work in progress	5,102	4,649
Finished goods	40,264	38,877
Total inventories	$ 66,764	$ 67,187

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Property, plant and equipment [Abstract]
Gross property, plant and equipment	$ 300,585	$ 307,746
Less: accumulated depreciation	112,549	113,407
Property, plant and equipment, net	188,036	194,339
Land
Property, plant and equipment [Abstract]
Gross property, plant and equipment	8,489	7,965
Building
Property, plant and equipment [Abstract]
Gross property, plant and equipment	68,844	67,702
Equipment
Property, plant and equipment [Abstract]
Gross property, plant and equipment	201,890	213,909
Construction in progress
Property, plant and equipment [Abstract]
Gross property, plant and equipment	$ 21,362	$ 18,170

INTANGIBLE ASSETS - Narrative (

INTANGIBLE ASSETS - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 446,453,000		$ 447,995,000
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Amortization of identifiable intangible assets	5,842,000	$ 6,193,000
Identifiable intangible assets with indefinite useful lives	0	$ 0
Discontinued Operations, Held-for-sale, Not Discontinued Operations | Human Nutrition & Health
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Goodwill	$ 1,380,000

INTANGIBLE ASSETS - Schedule of

INTANGIBLE ASSETS - Schedule of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Identifiable intangible assets [Abstract]
Gross carrying amount	$ 260,046	$ 260,370
Accumulated amortization	159,958	154,385
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of 2019	17,140
2020	20,878
2021	17,645
2022	16,151
2023	14,879
2024	$ 6,486
Customer relationships & lists
Identifiable intangible assets [Abstract]
Amortization period	10 years
Gross carrying amount	$ 192,120	192,185
Accumulated amortization	126,408	122,545
Trademarks & trade names
Identifiable intangible assets [Abstract]
Gross carrying amount	39,681	39,934
Accumulated amortization	$ 17,409	16,755
Trademarks & trade names | Minimum
Identifiable intangible assets [Abstract]
Amortization period	5 years
Trademarks & trade names | Maximum
Identifiable intangible assets [Abstract]
Amortization period	17 years
Developed technology
Identifiable intangible assets [Abstract]
Amortization period	5 years
Gross carrying amount	$ 13,338	13,338
Accumulated amortization	9,271	8,604
Other
Identifiable intangible assets [Abstract]
Gross carrying amount	14,907	14,913
Accumulated amortization	$ 6,870	$ 6,481
Other | Minimum
Identifiable intangible assets [Abstract]
Amortization period	3 years
Other | Maximum
Identifiable intangible assets [Abstract]
Amortization period	18 years

EQUITY-METHOD INVESTMENT (Detai

EQUITY-METHOD INVESTMENT (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)vote	Mar. 31, 2018USD ($)	Dec. 31, 2018USD ($)
Equity Method Investment, Summarized Financial Information [Abstract]
Percentage of production offtake	66.66%
Percentage of operating expenses to be absorbed	66.66%
St. Gabriel CC Company, LLC
Equity Method Investment, Summarized Financial Information [Abstract]
Ownership percentage in joint venture	66.66%
Loss relating to joint venture's expenses	$ 101	$ 139
Carrying value of joint venture	$ 4,801		$ 4,902
St. Gabriel CC Company, LLC | Eastman Chemical Company
Equity Method Investment, Summarized Financial Information [Abstract]
Ownership percentage in joint venture	33.34%
Number of votes | vote	2

REVOLVING LOAN (Details)

REVOLVING LOAN (Details) - USD ($)	Jun. 27, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	May 07, 2014
Line of Credit Facility [Abstract]
Outstanding balance		$ 140,000,000		$ 156,000,000
Capitalized costs net of accumulated amortization		1,197,000		$ 1,268,000
Amortization expense pertaining to capitalized costs		$ 71,000	$ 109,000
Credit Agreement
Line of Credit Facility [Abstract]
Senior secured credit agreement term	5 years
Maximum borrowing capacity	$ 500,000,000
Interest rate		3.496%
Commitment fee percentage		0.15%
Unused portion of revolving loan		$ 360,000,000
Credit Agreement | Minimum
Line of Credit Facility [Abstract]
Commitment fee percentage	0.15%
Credit Agreement | Maximum
Line of Credit Facility [Abstract]
Commitment fee percentage	0.275%
Term Loan A
Line of Credit Facility [Abstract]
Maximum borrowing capacity					$ 350,000,000
Payments for outstanding balance	$ 210,750,000
Revolving Credit Facility
Line of Credit Facility [Abstract]
Maximum borrowing capacity					$ 100,000,000
Installment payments required		$ 0

NET EARNINGS PER SHARE (Details

NET EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Net Earnings (Numerator)
Basic EPS – Net earnings and weighted average common shares outstanding	$ 18,783	$ 19,346
Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options, restricted stock, and performance shares	$ 18,783	$ 19,346
Number of Shares (Denominator)
Basic EPS – Net earnings and weighted average common shares outstanding (in shares)	32,188,469	31,985,332
Effect of dilutive securities - stock options, restricted stock, and performance shares (in shares)	320,663	342,001
Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options, restricted stock, and performance shares (in shares)	32,509,132	32,327,333
Per Share Amount
Basic EPS – Net earnings and weighted average common shares outstanding (in dollars per share)	$ 0.58	$ 0.60
Diluted EPS – Net earnings and weighted average common shares outstanding and effect of stock options, restricted stock, and performance shares (in dollars per share)	$ 0.58	$ 0.60
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive stock options outstanding, excluded from diluted earnings per share calculation (in shares)	515,573	347,211

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Effective tax rate	24.20%	23.20%
Unrecognized tax benefits	$ 5,648		$ 5,709
Accrued interest and penalties related to unrecognized tax benefits	$ 1,854		$ 1,839

SEGMENT INFORMATION - Narrative

SEGMENT INFORMATION - Narrative (Details)	3 Months Ended
	Mar. 31, 2019filling_facility
Segment Reporting [Abstract]
Number of filling facilities	2
Percentage decrease of chlorides released in environment	75.00%

SEGMENT INFORMATION - Business

SEGMENT INFORMATION - Business Segment Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Segment information [Abstract]
Assets	$ 971,888	$ 981,355
Other Unallocated
Segment information [Abstract]
Assets	41,805	59,473
Human Nutrition & Health | Operating Segments
Segment information [Abstract]
Assets	703,042	702,692
Animal Nutrition & Health | Operating Segments
Segment information [Abstract]
Assets	135,738	136,810
Specialty Products | Operating Segments
Segment information [Abstract]
Assets	65,715	59,558
Industrial Products | Operating Segments
Segment information [Abstract]
Assets	$ 25,588	$ 22,822

SEGMENT INFORMATION - Busines_2

SEGMENT INFORMATION - Business Segment Net Sales (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Segment information [Abstract]
Net sales	$ 157,029	$ 161,410
Human Nutrition & Health | Operating Segments
Segment information [Abstract]
Net sales	85,149	83,063
Animal Nutrition & Health | Operating Segments
Segment information [Abstract]
Net sales	43,361	46,141
Specialty Products | Operating Segments
Segment information [Abstract]
Net sales	18,424	17,740
Industrial Products | Operating Segments
Segment information [Abstract]
Net sales	$ 10,095	$ 14,466

SEGMENT INFORMATION - Busines_3

SEGMENT INFORMATION - Business Segment Earnings Before Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Segment information [Abstract]
Earnings before income taxes	$ 24,793	$ 25,177
Unallocated amortization expense	(5,842)	(6,193)
Interest and other (expense)	(1,687)	(2,063)
Other Unallocated
Segment information [Abstract]
Transaction costs, integration costs, and unallocated legal fees	(804)	(689)
Unallocated amortization expense	(9)	0
Human Nutrition & Health | Operating Segments
Segment information [Abstract]
Earnings before income taxes	13,703	12,932
Animal Nutrition & Health | Operating Segments
Segment information [Abstract]
Earnings before income taxes	5,256	7,484
Specialty Products | Operating Segments
Segment information [Abstract]
Earnings before income taxes	6,697	5,034
Industrial Products | Operating Segments
Segment information [Abstract]
Earnings before income taxes	$ 1,637	$ 2,479

SEGMENT INFORMATION - Depreciat

SEGMENT INFORMATION - Depreciation and Amortization (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Segment information [Abstract]
Depreciation/Amortization	$ 10,756	$ 11,018
Human Nutrition & Health | Operating Segments
Segment information [Abstract]
Depreciation/Amortization	7,986	8,532
Animal Nutrition & Health | Operating Segments
Segment information [Abstract]
Depreciation/Amortization	1,578	1,305
Specialty Products | Operating Segments
Segment information [Abstract]
Depreciation/Amortization	1,021	1,010
Industrial Products | Operating Segments
Segment information [Abstract]
Depreciation/Amortization	$ 171	$ 171

SEGMENT INFORMATION - Capital E

SEGMENT INFORMATION - Capital Expenditures (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Segment information [Abstract]
Capital expenditures	$ 8,488	$ 3,735
Human Nutrition & Health | Operating Segments
Segment information [Abstract]
Capital expenditures	5,255	2,079
Animal Nutrition & Health | Operating Segments
Segment information [Abstract]
Capital expenditures	1,471	830
Specialty Products | Operating Segments
Segment information [Abstract]
Capital expenditures	1,474	582
Industrial Products | Operating Segments
Segment information [Abstract]
Capital expenditures	$ 288	$ 244

REVENUE - Schedule of Disaggreg

REVENUE - Schedule of Disaggregation of Revenues (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)revenue_sub-stream	Mar. 31, 2018USD ($)
Revenue [Abstract]
Net sales	$ 157,029	$ 161,410
United States
Revenue [Abstract]
Net sales	118,111	120,668
Foreign Countries
Revenue [Abstract]
Net sales	38,918	40,742
Product Sales Revenue
Revenue [Abstract]
Net sales	$ 155,950	159,955
Number of sub-streams of revenue | revenue_sub-stream	4
Product Sales
Revenue [Abstract]
Net sales	$ 143,874	146,914
Co-manufacturing
Revenue [Abstract]
Net sales	10,630	10,707
Bill and Hold
Revenue [Abstract]
Net sales	857	1,289
Consignment
Revenue [Abstract]
Net sales	589	1,045
Royalty Revenue
Revenue [Abstract]
Net sales	$ 1,079	$ 1,455

SUPPLEMENTAL CASH FLOW INFORM_3

SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Supplemental Cash Flow Information [Abstract]
Income taxes	$ 58	$ 0
Interest	$ 1,459	$ 1,763

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Changes in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Changes in accumulated other comprehensive income (loss) [Abstract]
Net foreign currency translation adjustment	$ (1,089)	$ 1,363
Net change in postretirement benefit plan (see Note 15 for further information)
Amortization of prior service cost	18	18
Amortization of gain	(11)	(1)
Total before tax	7	17
Tax	(2)	(4)
Net of tax	5	13
Other comprehensive (loss) income	$ (1,084)	$ 1,376

ACCUMULATED OTHER COMPREHENSI_4

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Components of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 691,618	$ 616,881
Other comprehensive (loss)/income	(1,084)	1,376
Ending balance	710,509	639,890
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(3,602)	(1,642)
Other comprehensive (loss)/income	(1,084)	1,376
Ending balance	(4,686)	$ (266)
Foreign currency translation adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(4,285)
Other comprehensive (loss)/income	(1,089)
Ending balance	(5,374)
Postretirement benefit plan
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	683
Other comprehensive (loss)/income	5
Ending balance	$ 688

EMPLOYEE BENEFIT PLANS (Details

EMPLOYEE BENEFIT PLANS (Details)	3 Months Ended
	Mar. 31, 2019USD ($)plan	Mar. 31, 2018USD ($)	Dec. 31, 2018USD ($)
Defined Benefit Plan Disclosure [Line Items]
Number of defined benefit plans | plan	2
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Service cost	$ 16,000	$ 19,000
Interest cost	10,000	11,000
Amortization of prior service cost	18,000	18,000
Amortization of gain	(11,000)	(1,000)
Net periodic benefit cost	33,000	$ 47,000
Benefit obligation	1,200,000		$ 1,174,000
Unfunded, Nonqualified Deferred Compensation Plan
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Deferred compensation liability	1,513,000		265,000
Maximum
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Historical cash payments for retirement medical plan claims per year	100,000
Level 1
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Related rabbi trust assets	1,513,000		265,000
Level 1 | Other Noncurrent Assets
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Related rabbi trust assets	$ 1,513,000		$ 265,000

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Rent expense charged to operations under lease agreements	$ 813	$ 786
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
April 1, 2019 to December 31, 2019	2,562
2020	2,912
2021	2,005
2022	1,415
2023	1,176
2024	1,024
Thereafter	3,594
Total minimum lease payments	$ 14,688

FAIR VALUE OF FINANCIAL INSTR_2

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)	3 Months Ended
	Mar. 31, 2019USD ($)financial_instrument	Dec. 31, 2018USD ($)
Fair value of financial instruments [Abstract]
Number of financial instruments held for trading purposes | financial_instrument	0
Level 1
Fair value of financial instruments [Abstract]
Related rabbi trust assets	$ 1,513,000	$ 265,000
Money Market Funds | Level 1
Fair value of financial instruments [Abstract]
Cash and cash equivalents	$ 797,000	$ 793,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - St. Gabriel CC Company, LLC - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Related party transactions [Abstract]
Finished goods received from related party recorded in cost of goods sold	$ 5,312	$ 6,036
Receivable from related party	4,897		$ 3,210
Payable to related party	1,567		1,943
Related party payable related to non-contractual monies	310		$ 314
Services Provided
Related party transactions [Abstract]
Revenue from related party	868	927
Raw Materials Sold
Related party transactions [Abstract]
Revenue from related party	$ 6,808	$ 7,278

LEASES - Narrative (Details)

LEASES - Narrative (Details)	Mar. 31, 2019
Lessee, Operating Lease, Tranche One
Lessee, Lease, Description [Line Items]
Discount rate	3.45%
Lessee, Operating Lease, Tranche One | Minimum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	1 year
Lessee, Operating Lease, Tranche One | Maximum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	2 years
Lessee, Operating Lease, Tranche Two
Lessee, Lease, Description [Line Items]
Discount rate	4.04%
Lessee, Operating Lease, Tranche Two | Minimum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	3 years
Lessee, Operating Lease, Tranche Two | Maximum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	4 years
Lessee, Operating Lease, Tranche Three
Lessee, Lease, Description [Line Items]
Discount rate	4.38%
Lessee, Operating Lease, Tranche Three | Minimum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	5 years
Lessee, Operating Lease, Tranche Three | Maximum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	9 years
Lessee, Operating Lease, Tranche Four
Lessee, Lease, Description [Line Items]
Discount rate	5.10%
Term of contract for operating leases	10 years

LEASES - Schedule of Lease Cost

LEASES - Schedule of Lease Costs (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Lease Cost
Operating lease cost	$ 813
Other information
(Gains) and losses on sale and leaseback transactions, net	0
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	819
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 12,874
Weighted-average remaining lease term - operating leases	4 years 10 months 17 days
Weighted-average discount rate - operating	4.50%